![Illustrated close up of DNA.](/sites/default/files/styles/hero_xl/public/images/hero/Artboard1-80.jpg?h=1771c8c6&itok=-j_OtRem)
![Illustrated close up of DNA.](/sites/default/files/styles/hero_xl/public/images/hero/Artboard1-80.jpg?h=1771c8c6&itok=-j_OtRem)
To save researchers time and resources, The Michael J. Fox Foundation has made a number of tools available to the scientific community at low cost, with rapid delivery.
Helpful Resources
-
Sponsored Tools Program
Learn more about how MJFF can help share your tools.
-
Tools Consortium
MJFF is working with industry to develop priority tools.
-
Preclinical Models
Learn more about the various in vivo models used in Parkinson's disease research.
Find a Research Tool
Filter by Tool Type or Gene/Protein Type to Organize Results
* = MJFF does not control pricing or terms of availability for this tool.
Filters
AAV2-CBA-Alpha-Synuclein
Viral Vector
Unavailable. Viral vector (AAV2 serotype) encoding wild-type alpha-synuclein. Produced by the UNC Vector Core.
Characterization data for this viral vector can be found here.
AAV2/5-CBh-eBFP
Viral Vector
Viral Vector (AAV2/5 serotype) encoding eBFP to be used as a control for the AAv2/5 WT Human alpha-synuclein viral vector. This virus will not be made available as the QC/QA testing shows that it induces undesired inflammation and toxicity. Since stocks are available, groups may send a request for samples to tools@michaeljfox.org and may be granted access after vetting.
AAV2/5-CBh-Alpha-Synuclein
Viral Vector
Viral Vector (AAV2/5 serotype) encoding wild-type human alpha-synuclein. AAV2/5-CBh-empty vector control is available as a control (listed in the Control gene/protein type section) and the AAV-CBh-alpha-synuclein plasmid is available in the Plasmid section.
AAV2/5 Empty Vector Control
DNA Plasmids
Viral transgene plasmid used in the AAV empty vector control viral vector for the AAV WT human alpha-synuclein viral vector, both available through Charles River Labs (see viral vector section). This plasmid is available to non-profit and for-profit groups. RRID:Addgene_194245
AAV2/5 CBh WT Alpha-Synuclein Plasmid
DNA Plasmids
Viral transgene plasmid used in the AAV2/5 WT alpha-synuclein viral vector available through Charles River Labs (see viral vector section). This plasmid is available to non-profit and for-profit groups. RRID:Addgene_194244
AAV2/5 CBh Empty Vector Control
Viral Vector
Viral Vector (AAV2/5 serotype) to serve as a control vector for the AAV2/5-CBh-WT human alpha-synuclein viral vector. The AAV-CBh-empty vector plasmid is also available in the Plasmid section.
AAV1/2-CAG-Scrambled Control 3xSCRmiR/GFP
Viral Vector
CNS optimized viral vector (AAV1/2 pseudotype) encoding GFP and a scrambled control 3XmiR. To be used as a control vector with Mouse SNCA 3xmiR/GFP and Human SNCA 3xmiR/GFP. AAV 3xSCRmiR/GFP plasmid is available in the Plasmid section.
Generated as part of the Industry Tools Consortium.
AAV1/2-CAG-Mouse SNCA 3xmiR/GFP
Viral Vector
CNS optimized viral vector (AAV1/2 pseudotype) encoding GFP and 3XmiR to alpha-synuclein for specific knockdown of WT mouse a-syn and common pathogenic mutant forms (A53T, A30P, E46K). Scrambled Control 3xSCRmiR/GFP available as a control in Reporter section and AAV Mouse SNCA 3xmiR/GFP plasmid available in the Plasmid section.
Generated as part of the Industry Tools Consortium.
AAV1/2-CAG-Human SNCA 3xmiR/GFP
Viral Vector
CNS optimized viral vector (AAV1/2 pseudotype) encoding GFP and 3XmiR to alpha-synuclein for specific knockdown of WT human a-syn and common pathogenic mutant forms (A53T, A30P, E46K). Scrambled Control 3xSCRmiR/GFP available as a control in Reporter section and AAV Human SNCA 3xmiR/GFP plasmid available in the Plasmid section.
Generated as part of the Industry Tools Consortium.
AAV1/2-CAG-empty vector
Viral Vector
Viral Vector (AAV1/2 serotype) to serve as a control vector for the AAV1/2-CAG-A53T aSyn viral vector. The AAV-CAG-empty vector plasmid is also available in the Plasmid section.
Have questions or need additional information?
Email tools@michaeljfox.org with questions and to suggest new tools for us to develop. Or visit our FAQ page.
"We have shown, thanks in part to MJFF, that researchers now have in their pantry the right ‘ingredients’, to... help to drive forward PD drug development.”
Heather Melrose, PhD
Mayo Clinic